SCHEMBL4663326

SCHEMBL4663326

CS(=O)(=O)OCc1ccc(C=C2CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.40
▸ CA9 Q16790 3/20 0.40
▸ CA1 P00915 2/20 0.39
▸ PTPN1 P18031 2/20 0.36
▸ PTPN2 P17706 1/20 0.36
▸ PTPN11 Q06124 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ PTGS2 P35354 2/20 0.34
▸ HPGD P15428 2/20 0.33
▸ CYP24A1 Q07973 1/20 0.33
▸ PROKR1 Q8TCW9 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ SRD5A2 P31213 1/20 0.32
▸ XDH P47989 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4952656 0.80 CA2 (0.58) CA2CA9CA1PTPN1PTPN2
SCHEMBL2937687 0.79 CA2 (0.45) CA2CA9CA1PTPN1PTPN2
SCHEMBL7786902 0.77 CA2 (0.44) CA2CA9CA1PTPN1PTPN2
SCHEMBL29159482 0.77 CA2 (0.44) CA2CA9CA1PTPN1PTPN2
SCHEMBL19845815 0.74 CA2 (0.52) CA2CA9CA1KDM4ELMNA
SCHEMBL18030113 0.72 CA2 (0.68) CA2CA9CA1KMT2A
SCHEMBL4662063 0.72 CA2 (0.50) CA2CA9CA1KDM4ELMNA
SCHEMBL22211333 0.71 CA2 (0.48) CA2CA9CA1KDM4ELMNA
SCHEMBL22862366 0.71 CA2 (0.48) CA2CA9CA1CYP3A4
SCHEMBL15687370 0.71 CA2 (0.48) CA2CA9CA1PTPN1PTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1364957-B1 GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL (JP) 2008-12-31 — — EP disclosed
US-7189702-B2 Glucopyranosyloxypyrazole derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-03-13 — — US disclosed
US-7087579-B2 Glucopyranosyloxypyrazole derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2006-08-08 — — US disclosed
US-20060142209-A1 Glucopyranosyloxypyrazole derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. 2006-06-29 — — US disclosed
US-20040132669-A1 Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs KISSEI PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 — — US disclosed
EP-1364957-A1 GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2003-11-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132669-A1 Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs SLC5A2, SLC5A1, SLC2A1 CA2 413/4885CA9 503/4885CA1 3096/4885
US-20060142209-A1 Glucopyranosyloxypyrazole derivatives and medicinal use thereof SLC5A2, SLC5A1, UGGT1 CA2 1252/4885CA9 1329/4885CA1 3922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback